# ClinicalTrials.gov record NCT07684144

> PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07684144-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-03
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07684144-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07684144-maridebart-cafraglutide-v1.json
- Content SHA-256: `3fd367faf0442041dede559360692d07ffd761e8c9d111a2e580866fa56613a2`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07684144 ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07684144-2026-09-03-55c606c96523`](#source-ctg-observation-nct07684144-2026-09-03-55c606c96523))

## Sources

<a id="source-ctg-observation-nct07684144-2026-09-03-55c606c96523"></a>
- **ClinicalTrials.gov record NCT07684144 · retained source version 2026-09-03:55c606c96523ea42d404f5617e5f68a2c197af4f8392d7f3ab505d7bdf0c5e7a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07684144) (`ctg-observation-nct07684144-2026-09-03-55c606c96523`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07684144." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07684144-maridebart-cafraglutide-v1.json SHA-256: 3fd367faf0442041dede559360692d07ffd761e8c9d111a2e580866fa56613a2.